Guggenheim Maintains a Hold on Amgen Inc. (AMGN)

Amgen Inc. (NASDAQ:AMGN) is one of the best cheap stocks to buy for beginners. In a report released on September 5, Vamil Divan from Guggenheim maintained a Hold rating on Amgen Inc. (NASDAQ:AMGN), setting a price target of $288.00.

Dogs of the Dow: Why Amgen’s (AMGN) Dividend Power Makes it a Standout Pick

Amgen Inc. reported its fiscal Q2 2025 earnings on August 5, with t0tal revenues increasing 9% to $9.2 billion compared to Q2 2024. GAAP earnings per share (EPS) rose 92% from $1.38 to $2.65, primarily attributed to higher revenues.

Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.